Chongqing Fuchuang Pharmaceutical Research

Chongqing Fuchuang Pharmaceutical Research is a clinical-stage biotechnology company and a key R&D subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Founded in 2009, the company focuses on the discovery and development of innovative small molecule drugs, particularly in the fields of oncology and ophthalmology. Its pipeline includes several high-potential candidates such as FCN-159, a MEK inhibitor with Breakthrough Therapy Designation in China for neurofibromatosis, and FCN-338, a BCL-2 inhibitor for B-cell malignancies. Fuchuang operates research facilities in Chongqing and Shanghai, leveraging its expertise in medicinal chemistry and pharmacology to address significant unmet medical needs.